Numbers

The Numbers

Thesis. Synchrony trades at roughly 8x trailing earnings because the market has already paid for most of the credit-cycle recovery — the stock doubled off its April-2025 lows before giving some back. The numbers confirm what the tape implies: net charge-offs have rolled from a 6.3% peak to 5.4% over four quarters, TTM EPS has climbed from a $5.19 trough (FY2023) to $9.66, and the diluted share count is down 39% since FY2021. The single metric most likely to rerate or derate the stock from here is through-cycle net charge-off rate. Settle at 5.0–5.25% and EPS power is closer to $4.5B than $3.5B; re-accelerate past 6% and the 8x multiple compresses toward book value.

Snapshot

Price (21-Apr-2026)

$77.63

Market Cap ($B)

27.0

P/E (TTM)

8.0

EPS (TTM)

$9.66

Quality Score (0–100)

Fair Value 12m ($)

$94.14

Loan Book ($B)

105

Quality Score is a composite 0–100 measure of earnings durability, balance-sheet strength, and return consistency. Fair Value (12-month) is the consensus analyst mean across 17 covering sell-side shops, implying roughly 21% upside from today's $77.63. Both are scale-normalized — not a signal to buy or sell on their own.

1. Quality scorecard — is this a well-run business?

Six operating ratios capture whether the credit machine is working. For a private-label card specialist, these are the ones that matter — revenue growth is almost irrelevant next to them.

No Results

Six of seven gauges read green. Efficiency ratio has drifted from 30.0 (FY2024) into the 35–36 zone on a trailing basis as management funds Dual Card growth and the PRISM decisioning platform; that is the single metric to watch next quarter. Everything else is improving in the direction that history says precedes multiple expansion in this business.

2. Revenue & earnings power — 5-year view

Reported revenue is boring: $14B–$18B net interest income, gently up. The story is not at the top of the P&L — it is at the bottom, where provisioning for credit losses swings net income by more than 60% peak-to-trough.

FY2024 includes a one-time $1.04B pre-tax gain from the Pets Best divestiture which boosted reported EPS. FY2025 is presented on a net-interest-income basis from the quarterly disclosures.

NII compounded from $14.2B to $18.0B between FY2021 and FY2024 — a boring 8% CAGR. EPS went $7.34 → $5.19 → $8.55 → $9.29 over the same window, a 73% peak-to-peak swing that has nothing to do with revenue and everything to do with (a) where the credit cycle was and (b) how many shares were outstanding.

Quarterly revenue vs provision — the swing engine

1Q24 revenue and net income include a ~$1.04B pre-tax gain from the Pets Best divestiture — the rest of the series is like-for-like operating results.

Provision ran at $1.56B–$1.88B per quarter through 2024, dropped to $1.15B in Q2–Q3 2025 (the "normalization" investors had been waiting for), spiked to $1.44B in Q4 on a year-end reserve review, and came in at $1.33B in Q1 2026. Each $100M move in provision is roughly $0.22 of quarterly EPS at current share count. Revenue has been mechanically flat around $3.7B for seven straight quarters — this is not a growth stock in any useful sense.

3. Cash generation — are the earnings real?

Synchrony is a bank, so the traditional "operating cash flow vs net income" test is less informative than for an industrial or SaaS company — the cash engine is interest earned on loans, and FCF-style metrics are dominated by loan-book growth. The right version of the "are the earnings real" test for a consumer lender is pre-provision net revenue (PPNR) vs net charge-offs — does the operating earnings engine, before credit loss recognition, cover the actual cash losses on the portfolio?

Pre-provision net revenue estimated as net interest income plus other income less non-interest expense. Actual NCO dollars estimated from NCO rate times average loan receivables.

PPNR covers actual NCOs in every year of the cycle — even at the 2024 peak, $8.4B of pre-provision earnings absorbed $6.3B of losses with $2.1B left over. This is the real cash-generation test for a subprime card book, and SYF passes it across every vintage of the cycle. The coverage ratio narrowed to roughly 1.3x in 2024 (versus 3.9x in 2021), and has since re-widened as NCOs roll off.

4. Capital allocation — where the return came from

Synchrony is a buyback machine. Understanding the share-count trajectory is more important than understanding the income statement.

The share count is down 39% in five years. That is the single largest contributor to EPS growth over the cycle. A constant-share-count SYF would have reported $5.97 TTM EPS instead of $9.66 — the buyback alone is worth $3.69 of incremental EPS. Dividend is $1.20 annualized (1.5% yield, 12.9% payout ratio): management's philosophy is that almost all excess capital goes into buybacks, not dividends.

**The buyback flywheel works only if the stock stays cheap.** At 8x earnings, every dollar of buyback retires more earnings than it would at 15x. If the multiple rerates toward mid-teens, management has to decide whether to keep repurchasing or accumulate capital for the next cycle. The cheapness is the opportunity — and also the ceiling on this flywheel.

5. Balance sheet — the boring engine

Synchrony runs a very simple capital stack: $105B of consumer loans, funded by $82B of FDIC-insured deposits at Synchrony Bank, with 13.3% CET1 as the cushion.

Deposits have funded 78–83% of receivables across the cycle — this is the source of SYF's structural funding cost advantage and why NIM stays at 15% while peers dependent on wholesale funding see margins compress when rates move. CET1 spiked to 16.1% in 2021 (covid capital build), drifted to 12.2% in 2023 as buybacks resumed, and rebounded to 13.3% — comfortable cushion over the 8% regulatory minimum. Basel III standardized-approach transition could free another 125–150 bp of capital, which is the quiet call option on future buyback capacity.

6. The credit cycle — where the earnings live

FY2025 and FY2026 figures are trailing-period estimates from quarterly disclosures. Through-cycle NIM has anchored near 15% across every year of the cycle.

NIM hugs 15% — funding costs move, asset yields move, and the two largely offset. NCO is where the cycle lives. Q1 2026 prints 5.42%, down 96 basis points year-on-year and 89 bp below the FY2024 peak. For a $100B loan book, every 100 bp of NCO improvement is roughly $1B of pre-tax earnings.

**Critical insight.** Management has been tightening underwriting since late 2022. The 2025–26 origination vintages are structurally better credit than the 2022 vintages that produced the 2024 NCO peak. Payment rate at 16.3% is 110 bp above the 14–15% pre-pandemic baseline — a leading indicator of future loss rates that the consensus is not yet pricing in. Through-cycle losses settling near 5.0–5.25% rather than 5.5–6.0% is where the upside case lives.

7. Valuation — 10-year price and P/E history (the critical chart)

**This is the critical chart on the page.** It tells you what the market has historically paid for Synchrony's earnings stream. The answer: not much, and not recently more.

SYF has almost never traded rich. The 10-year P/E range is 5.3x–15.3x with a 7.8x median; the current 8.0x is above the 5-year mean of 7.3x but in the lower half of the 10-year range. The stock rerated hard in 2024–25 — the easy multiple expansion is done. From here, price tracks EPS growth, not further re-rating. Against the S&P 500 around 24x and the peer median near 11–12x, SYF remains structurally cheap — a function of the private-label business model trading at a discount to more diversified consumer-finance models, not a signal of obvious mispricing.

8. Peer comparison

No Results

Only AXP sits clearly above SYF on the quality axis (34% ROTCE vs. 22.6%), and AXP trades at roughly 20x earnings for that quality. SYF earns 22.6% ROTCE — better than every peer except AXP — and trades at 8x. That gap is the structural discount for "private-label card issuer" as a business model, not a reflection of quality. BFH, the cleanest direct comparable, runs 14% ROTCE with an inferior efficiency ratio and trades below SYF on P/E — which tells you the market rewards SYF for its scale even within the private-label niche.

9. Fair value & scenario

Three reference points triangulate a fair-value range for the next twelve months.

No Results

Consensus is exactly where the numbers would put you. 17 analysts carry a median price target of $84 and a mean of $85 — 8–10% upside from $77.63. The tight clustering of targets ($71–$103) signals a consensus view that the credit path is understood and priced. From here, it is not a re-rating story — it is an EPS story. Every quarter of NCO printing under 5.5% adds 5–10% to the price; every quarter above 5.5% takes the same amount off.

Bottom line

The numbers confirm a business whose earnings cycle has turned: charge-offs normalizing from 6.3% to 5.4%, NIM stable at 15%, CET1 rebuilt to 13.3%, efficiency competitive at 30–36%, and ROTCE at 22.6% putting SYF behind only AXP in the peer set. The numbers contradict the narrative that SYF is still a beaten-up consumer-credit play — the stock has already doubled off its 2025 low, and at 8x TTM earnings on $9.66 EPS it is priced for the normalization story, not waiting for it. Watch next quarter for (a) the provision-to-revenue ratio — any drop under 32% is a signal through-cycle losses are settling at the low end of the range; (b) the Q2 reserve release or build, which will tell you how management sees vintage quality; and (c) the pace of share repurchases, which is the marginal EPS driver until credit improves further.